Department of Obstetrics and Gynecology, ACIBADEM Kayseri Hospital, Kayseri, Turkey.
Obstet Gynecol Surv. 2010 Oct;65(10):653-67. doi: 10.1097/OGX.0b013e3182095366.
To perform a systematic review and meta-analysis of the effectiveness of combined vitamin C and E (vitCE) supplementation for the prevention of preeclampsia.
PubMED, Web of Science, and Cochrane Central Register of Controlled Trials from inception through June 2010, and bibliographies of review articles and eligible studies.
Fifteen eligible studies that evaluated vitCE supplementation for the prevention of preeclampsia were identified. On the basis of prespecified inclusion and exclusion criteria, 9 were included in the meta-analysis. All were randomized controlled trials. The reporting and methodologic quality of the included studies was assessed with the CONSORT checklist and the Jadad scale.
TABULATION, INTEGRATION, AND RESULTS: The 9 included studies had moderate-to-high CONSORT and Jadad scores. The incidence of preeclampsia was 9.7% (949 of 9833) in the vitCE group and 9.5% (946 of 9842) in the placebo group. A random effects model was used for pooling and no difference was found in the relative risk (RR) of preeclampsia between the vitCE and placebo groups (RR: 0.98; 95% confidence interval [CI]: 0.87-1.10). The incidence of gestational hypertension was 22.6% (1915 of 8491) in the vitCE group and 20.3% (1728 of 8500) in the placebo group (RR: 1.11, 95% CI: 1.05-1.17). The incidence of placental abruption was 0.58% (43 of 7379) in the vitCE group and 0.87% (64 of 7361) in the placebo group (RR: 0.67, 95% CI: 0.46-0.98). No significant differences were observed for other maternal and neonatal outcomes.
Combined VitCE supplementation does not decrease the risk of preeclampsia and should not be offered to gravidas for the prevention of preeclampsia or other pregnancy induced hypertensive disorders. Furthermore, combined supplementation with vitCE increased the risk of GH but decreased the risk of placental abruption. However, these latter associations may not be causal, especially since they were the product of multiple statistical comparisons, and the 95% CI around the point estimates almost included one.
After completion of this educational activity, the obstetrician/gynecologist should be better able to assess the causes of preeclampsia and related conditions; evaluate and interpret the evidence regarding the use of combined vitamins C and E in prevention of preeclampsia and related conditions; and interpret and understand the effects of the supplementation of vitamins C and E for the prevention of preeclampsia or other pregnancy induced hypertensive disorders.
Obstetricians & Gynecologists, Family Physicians.
对维生素 C 和 E(vitCE)联合补充预防子痫前期的有效性进行系统评价和荟萃分析。
Pubmed、Web of Science 和 Cochrane 对照试验中心注册库,从成立到 2010 年 6 月,以及综述文章和合格研究的参考文献。
确定了 15 项评估 vitCE 补充预防子痫前期的合格研究。根据预设的纳入和排除标准,9 项研究被纳入荟萃分析。所有研究均为随机对照试验。使用 CONSORT 清单和 Jadad 量表评估纳入研究的报告和方法学质量。
列表、综合和结果:9 项纳入研究的 CONSORT 和 Jadad 评分均为中等到高。vitCE 组子痫前期的发生率为 9.7%(9833 例中的 949 例),安慰剂组为 9.5%(9842 例中的 946 例)。采用随机效应模型进行汇总,vitCE 组与安慰剂组子痫前期的相对风险(RR)无差异(RR:0.98;95%置信区间[CI]:0.87-1.10)。vitCE 组妊娠高血压的发生率为 22.6%(8491 例中的 1915 例),安慰剂组为 20.3%(8500 例中的 1728 例)(RR:1.11,95%CI:1.05-1.17)。vitCE 组胎盘早剥的发生率为 0.58%(7379 例中的 43 例),安慰剂组为 0.87%(7361 例中的 64 例)(RR:0.67,95%CI:0.46-0.98)。其他母婴和新生儿结局无显著差异。
联合 VitCE 补充不能降低子痫前期的风险,不应为预防子痫前期或其他妊娠相关高血压疾病而向孕妇提供。此外,vitCE 联合补充增加了 GH 的风险,但降低了胎盘早剥的风险。然而,这些关联可能不是因果关系,尤其是因为它们是多次统计比较的产物,点估计值的 95%CI 几乎包含一个。
完成本项教育活动后,妇产科医生应能够更好地评估子痫前期和相关疾病的病因;评估和解释关于维生素 C 和 E 联合用于预防子痫前期和相关疾病的证据;解释和理解补充维生素 C 和 E 预防子痫前期或其他妊娠相关高血压疾病的效果。
妇产科医生、家庭医生。